Abstract
Objectives: To describe the clinical and biological features of a series of immunophenotypic variant of B-CLL (v-CLL) characterised by intermediate RMH score, in the absence of t(11;14)(q13;q32) in FISH analysis in comparison with a series of typical CLL. Methods: We studied the clinical and biological features of 63 cases of v-CLL and 130 cases of CLL. Results: We observed significant differences in terms of age 9/L (P <0.001), lymphocyte doubling time ≤12 months (P = 0.02), high serum β2-microglobulin levels (P <0.001) and splenomegaly (P = 0.002); CD38, CD49d, CD1c were more expressed in v-CLL, CD43 in CLL (P <0.001). IgV H mutation and trisomy 12 were more frequent in v-CLL group (P = 0.001; P <0.001); del13q14 in CLL (P = 0.008). Gene expression profiling of nine v-CLL and 60 CLL indicated that the atypical group presented a specific molecular pattern. After a median follow-up of respectively, 55 (4-196) and 60 months (6-180), 25/42 patients with v-CLL (48%) and 55/93 patients with CLL (59%) were treated. Time to treatment was significantly shorter in IgV H-mutated v-CLL vs. mutated CLL (P = 0.006). The median overall survival was worse in v-CLL-mutated cases (P = 0.062). Conclusion: v-CLL should be identified and dealt with separately from classic CLL. In particular, the prognostic markers that are routinely used to characterise classical B-CLL should not be interpreted as having the same meaning.
| Original language | English |
|---|---|
| Pages (from-to) | 120-129 |
| Number of pages | 10 |
| Journal | European Journal of Haematology |
| Volume | 85 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Aug 2010 |
Fingerprint
Keywords
- B-cell chronic lymphocytic leukaemia
- FISH analysis
- IgV gene mutations
- immunophenotype
- ZAP-70 expression
ASJC Scopus subject areas
- Hematology
Cite this
The clinical and biological features of a series of immunophenotypic variant of B-CLL. / Cro, Lilla; Ferrario, Andrea; Lionetti, Marta; Bertoni, Francesco; Zucal N, Nadia; Nobili, Lucia; Fabris, Sonia; Todoerti, Katia; Cortelezzi, Agostino; Guffanti, Andrea; Goldaniga, Maria; Marcheselli, Luigi; Neri, Antonino; Lambertenghi-Deliliers, Giorgio; Baldini, Luca.
In: European Journal of Haematology, Vol. 85, No. 2, 08.2010, p. 120-129.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The clinical and biological features of a series of immunophenotypic variant of B-CLL
AU - Cro, Lilla
AU - Ferrario, Andrea
AU - Lionetti, Marta
AU - Bertoni, Francesco
AU - Zucal N, Nadia
AU - Nobili, Lucia
AU - Fabris, Sonia
AU - Todoerti, Katia
AU - Cortelezzi, Agostino
AU - Guffanti, Andrea
AU - Goldaniga, Maria
AU - Marcheselli, Luigi
AU - Neri, Antonino
AU - Lambertenghi-Deliliers, Giorgio
AU - Baldini, Luca
PY - 2010/8
Y1 - 2010/8
N2 - Objectives: To describe the clinical and biological features of a series of immunophenotypic variant of B-CLL (v-CLL) characterised by intermediate RMH score, in the absence of t(11;14)(q13;q32) in FISH analysis in comparison with a series of typical CLL. Methods: We studied the clinical and biological features of 63 cases of v-CLL and 130 cases of CLL. Results: We observed significant differences in terms of age 9/L (P <0.001), lymphocyte doubling time ≤12 months (P = 0.02), high serum β2-microglobulin levels (P <0.001) and splenomegaly (P = 0.002); CD38, CD49d, CD1c were more expressed in v-CLL, CD43 in CLL (P <0.001). IgV H mutation and trisomy 12 were more frequent in v-CLL group (P = 0.001; P <0.001); del13q14 in CLL (P = 0.008). Gene expression profiling of nine v-CLL and 60 CLL indicated that the atypical group presented a specific molecular pattern. After a median follow-up of respectively, 55 (4-196) and 60 months (6-180), 25/42 patients with v-CLL (48%) and 55/93 patients with CLL (59%) were treated. Time to treatment was significantly shorter in IgV H-mutated v-CLL vs. mutated CLL (P = 0.006). The median overall survival was worse in v-CLL-mutated cases (P = 0.062). Conclusion: v-CLL should be identified and dealt with separately from classic CLL. In particular, the prognostic markers that are routinely used to characterise classical B-CLL should not be interpreted as having the same meaning.
AB - Objectives: To describe the clinical and biological features of a series of immunophenotypic variant of B-CLL (v-CLL) characterised by intermediate RMH score, in the absence of t(11;14)(q13;q32) in FISH analysis in comparison with a series of typical CLL. Methods: We studied the clinical and biological features of 63 cases of v-CLL and 130 cases of CLL. Results: We observed significant differences in terms of age 9/L (P <0.001), lymphocyte doubling time ≤12 months (P = 0.02), high serum β2-microglobulin levels (P <0.001) and splenomegaly (P = 0.002); CD38, CD49d, CD1c were more expressed in v-CLL, CD43 in CLL (P <0.001). IgV H mutation and trisomy 12 were more frequent in v-CLL group (P = 0.001; P <0.001); del13q14 in CLL (P = 0.008). Gene expression profiling of nine v-CLL and 60 CLL indicated that the atypical group presented a specific molecular pattern. After a median follow-up of respectively, 55 (4-196) and 60 months (6-180), 25/42 patients with v-CLL (48%) and 55/93 patients with CLL (59%) were treated. Time to treatment was significantly shorter in IgV H-mutated v-CLL vs. mutated CLL (P = 0.006). The median overall survival was worse in v-CLL-mutated cases (P = 0.062). Conclusion: v-CLL should be identified and dealt with separately from classic CLL. In particular, the prognostic markers that are routinely used to characterise classical B-CLL should not be interpreted as having the same meaning.
KW - B-cell chronic lymphocytic leukaemia
KW - FISH analysis
KW - IgV gene mutations
KW - immunophenotype
KW - ZAP-70 expression
UR - http://www.scopus.com/inward/record.url?scp=77954719731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954719731&partnerID=8YFLogxK
U2 - 10.1111/j.1600-0609.2010.01454.x
DO - 10.1111/j.1600-0609.2010.01454.x
M3 - Article
C2 - 20408870
AN - SCOPUS:77954719731
VL - 85
SP - 120
EP - 129
JO - European Journal of Haematology
JF - European Journal of Haematology
SN - 0902-4441
IS - 2
ER -